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Figure 1 Potential therapeutic targets to slow or prev
spread of tau pathology in the brain (Pooler et al., 2013).
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Alzheimer’s disease (AD) is a neurodegenerative disorder and
considered the most common form of dementia. Although
signiﬁcant development has been made in AD research dur-
ing the last few years, much remains to be understood. For
instance, no disease-modifying therapeutic agents are avail-
able to delay AD onset (Moulder et al., 2013). Five therapies
have been approved for AD. Four of these medications are
classiﬁed together as cholinesterase inhibitors (CIs); these
are approved for dementia of the Alzheimer’s type in the
mild-to-moderate stage. These include tacrine, donepezil, riv-
astigmine, and galantamine. Some critics, especially those
concerned with conserving rare resources, have alleged that
these drugs are not cost effective enough to warrant the
expense. Patients and their advocates, looking at the same
data but with a different perspective, often come to the oppo-
site conclusion. One the other hand, critics have found to
focus on limitations in the methodology of clinical trials
and on bias in the way the data are introduced, especially
in trials sponsored by drug companies, and have concluded
that efﬁcacy of drugs is inﬂated (Casey et al., 2010). One of
the most important problems leading to difﬁculty in disease
management is AD pathology existed in brain cells many
years before the appearance of clinical symptoms (Price
et al., 2009). AD is distinguished mainly by neuronal loss.
Furthermore, it is characterized by two hallmark lesions:
amyloid-b-containing plaques and neuroﬁbrillary tangles
(NFTs). In AD, NFTs accumulate leaving an impact on some
brain regions that are responsible for memory and learning
(Hyman et al., 1984). Under pathological conditions, tau pro-
tein, which regulates the dynamics of neurons in the brain,becomes abnormally phosphorylated and aggregates into
the so-called NFTs (Duyckaerts et al., 2009).
Tau protein is considered a target for the development of
novel drugs aiming to treat AD as inhibiting the intercellular
transfer of tau may slow the progression of tau pathology.
Therapeutic strategies for reducing the interneuronal transfer
of tau may achieved through different patterns as shown in
Fig. 1: inhibiting tau release, reducing accumulation of extra-
cellular tau, or preventing tau uptake (Pooler et al., 2013).
Some researchers suggest the utilization of Histone deace-
tylase (HDAC6) inhibition to enhance tau acetylation as a
recent therapeutic strategy for management of AD. HDAC6
inhibitors prevent phosphorylation of tau, so interfering with
tau’s ability to aggregate. Lowering HDAC6 activity also
enhances microtubule stability and transport, which is thought
to stimulate neuronal function (Cook et al., 2014).
In conclusion, the available drugs for AD are insufﬁcient to
manage this disorder appropriately. There is a high unmet
need to develop more advanced drugs. Agents acting on tau
protein as a target show some promising outcome in the
clinical trials.ent the
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